Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at $120.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Cytokinetics’ drug, aficamten, for treating cardiac conditions. The recent analyses presented by Cytokinetics underscore aficamten’s efficacy in cardiac remodeling, which is a significant aspect of its therapeutic promise. These findings, which are set to be showcased at the upcoming Annual American College of Cardiology Scientific Session & Expo 2025, reinforce the drug’s long-term benefits on cardiac structure and function.
Furthermore, the data indicates that aficamten maintains its efficacy even when used in conjunction with or following the withdrawal of disopyramide, a standard treatment for obstructive hypertrophic cardiomyopathy (oHCM). The favorable outcomes from extended treatment periods, including reductions in left ventricular mass and left atrial size without progression of myocardial fibrosis, bolster the drug’s profile. These insights contribute to Pantginis’s confidence in aficamten’s potential, supporting his Buy recommendation for Cytokinetics’ stock.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and VYNE Therapeutics. According to TipRanks, Pantginis has an average return of -12.4% and a 25.60% success rate on recommended stocks.
In another report released on March 10, Morgan Stanley also maintained a Buy rating on the stock with a $67.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com